# Keros Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/keros-therapeutics

- Industry: Biotechnology
- Headquarters: Lexington, US
- Website: www.kerostx.com/
- Total disclosed funding: $68M
- Latest round: Series C (Mar 2, 2020)
- Investors on record: 10

## About

Based in Massachusetts, US, and founded in 2016, Keros Therapeutics, Inc. operates as a provider of therapies that modulate TGF-ß signaling for patients with conditions affecting blood cells, bone, skeletal muscle, adipose tissue, and heart tissues. progressive (FOP), which promotes the transformation of muscle into bone. In January 2024, Keros Therapeutics, Inc. raised USD 140 million in a private placement, selling 3.5 million shares at USD 40 per share. The firm trades on NASDAQ under the ticker symbol KROS. As of 2024, the company is led by its CEO, Jasbir Seehra, Ph.D.

The company provides a wide range of therapeutic products, such as KER-050 for ineffective hematopoiesis in myelodysplastic syndromes and myelofibrosis, KER-012 for pulmonary arterial hypertension, and KER-065 for obesity and neuromuscular diseases. Additionally, the firm also provides research services focused on developing new treatment options for diseases with unmet medical needs.

## Funding rounds

- Series C, Mar 2, 2020, $56M — OrbiMed Advisors, Healthcare Royalty Partners, Venrock, Pontifax Venture Capital, Mass General Brigham Ventures, Foresite Capital, Arkin Capital, Quark Venture, Medison Pharma
- Series B, Nov 9, 2018, $12M — Pontifax Venture Capital, Mass General Brigham Ventures, GF Securities, Arkin Capital, Quark Venture, Medison Pharma

## Investors

- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series B, Series C
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series B, Series C
- GF Securities — Series B
- Arkin Capital (https://capitalatlas.ai/funds/arkin-capital) — Series B, Series C
- Quark Venture (https://capitalatlas.ai/funds/quark-venture) — Series B, Series C
- Medison Pharma — Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Healthcare Royalty Partners (https://capitalatlas.ai/funds/healthcare-royalty-partners) — Series C
- Venrock (https://capitalatlas.ai/funds/venrock) — Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C